Singapore-based Nanyang Biologics has entered a $1.5 billion business combination agreement with Nasdaq-listed special purpose acquisition company RF Acquisition Corp II. The biotech leverages AI merged with natural compound libraries to accelerate drug discovery across multiple modalities. The transaction, expected to complete by Q2 2026, positions Nanyang Biologics to establish one of the world's largest AI-curated natural compound collections and to advance diversified preclinical pipeline candidates targeting oncology and other diseases.